This category covers biotechnology and pharmaceutical companies developing therapeutics that target glucocerebrosidase (GBA) for Parkinson's disease treatment. GBA mutations represent the most common genetic risk factor for PD, increasing risk 5-20x and accounting for approximately 5-10% of all PD cases[1]. The therapeutic approaches listed here aim to restore GBA enzyme function, reduce toxic substrate accumulation, or address the downstream effects of GBA dysfunction on alpha-synuclein pathology[2].
Gene therapy aims to deliver a functional GBA1 gene to restore glucocerebrosidase activity in the central nervous system. This approach offers potential for long-term disease modification.
Molecular chaperones are small molecules that stabilize mutant GBA enzymes, improving their folding, trafficking, and enzymatic activity. This approach can restore partial enzyme function.
Substrate reduction therapy (SRT) reduces glucosylceramide accumulation by inhibiting its synthesis upstream of GBA.
Beyond direct GBA targeting, these companies address lysosomal dysfunction through complementary mechanisms.
Enzyme replacement therapy (ERT) involves intravenous administration of recombinant GBA. Challenges include blood-brain barrier penetration.
| Drug | Company | Status |
|---|---|---|
| Taliglucerase alfa (Elelyso) | Pfizer | Approved |
| Velaglucerase alfa (VPRIV) | Takeda | Approved |
| Imiglucerase (Cerezyme) | Sanofi | Approved |
Note: These are approved for Gaucher disease but do not cross the BBB for PD treatment.
| Approach | Mechanism | Advantages | Challenges |
|---|---|---|---|
| Gene Therapy (AAV-GBA) | Deliver functional GBA1 gene | Long-term expression, single administration | Invasive delivery, immune response |
| Molecular Chaperones | Stabilize mutant GBA | Oral dosing, reversible | Partial activity restoration |
| Substrate Reduction | Inhibit glucosylceramide synthesis | Well-characterized mechanism | May affect other pathways |
| Lysosomal Ion Channels | Enhance lysosomal function | Broader mechanism | Preclinical stage |
| Enzyme Replacement | Add functional enzyme | Direct enzyme replacement | Does not cross BBB |
| Trial | Company | Drug | Phase | Status |
|---|---|---|---|---|
| PROVIEW | Prevail/Lilly | PR001 | Phase 1/2 | Enrolling |
| IMAGINE | Passage Bio | PBFT02 | Phase 1 | Enrolling |
| NCT06732180 | Gain Therapeutics | GT-02287 | Phase 1b | Recruiting |
| NCT04144088 | Sanofi | Venglustat | Phase 2 | Completed |